BRCA1 and ovarian cancer: In contrast, Tala + Deci also potentiated death in two independent BRCA1 mutant ovarian cancer cell lines (Fig. 3E; COV362, up to ~ 58% death; and Fig. 3F; JHOS2 up to 35% death).